<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Sat, 02 May 2026 18:33:46 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[企業] Lillyが今年の売り上げ予想を820〜850億ドルへと引き上げ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109774&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109774&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 業績発表・予想</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 02 May 2026 18:33:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109774&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] アルツハイマー病アジテーションへのAxsome社のAuvelity使用を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109773&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109773&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 02 May 2026 09:08:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109773&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Arvinas/Pfizerが売り手を探している乳癌薬Veppanuを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109772&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109772&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 02 May 2026 08:42:04 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109772&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 点鼻インフルエンザワクチンFluMistは上気道のメモリーB細胞反応を引き出す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109771&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109771&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 02 May 2026 06:17:48 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109771&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] HBV慢性感染の治癒を意味するHBsAg消失にはCD4+T細胞の働きが不可欠らしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109770&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109770&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 02 May 2026 05:13:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109770&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] AVVが運ぶ抗CCR5抗体発現遺伝子治療がサルのHIV同等ウイルスの複製を抑制</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109769&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109769&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 21:03:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109769&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 移植した網膜神経節細胞が内境界膜を始末することで助かる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109768&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109768&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 18:29:16 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109768&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Nav1.5チャネルを介したナトリウム電流にもDPP6が携わる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109767&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109767&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 17:41:01 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109767&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Alector/GSKのプログラニュリン底上げ薬のアルツハイマー病Ph2試験中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109766&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109766&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止 || 開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 11:03:42 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109766&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] より初期を含む多発性骨髄腫患者相手のPh3試験でPfizerのElrexfioが目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109765&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109765&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 10:31:19 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109765&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ChiesiがKalVistaを買って遺伝性血管浮腫薬Ekterlyを手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109764&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109764&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 09:30:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109764&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 固形癌Ph1試験段階KRAS阻害薬のKestrel社をAbbVieが気が向いたら買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109763&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109763&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 07:52:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109763&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ゲノムの目当ての地点にはまるリコンビナーゼをLillyがProfluentに設計してもらう</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109762&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109762&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 01 May 2026 06:15:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109762&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaの3成分吸入薬Breztri Aerosphereの喘息用途を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109761&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109761&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 30 Apr 2026 15:07:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109761&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 妊娠高血圧腎症の妊婦にsFlt-1除去血液ろ過が有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109760&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109760&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 30 Apr 2026 11:27:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109760&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph2試験段階の筋症遺伝子治療とPh1試験段階の2つをアステラス製薬が中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109759&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109759&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験 || 開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 16:17:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109759&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 太い成人の体重がBI社のグルカゴンとGLP-1の両取り薬survodutideで17%弱低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109758&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109758&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 15:51:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109758&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Erasca社のGTP結合RAS標的薬ERAS-0015のPh1試験の肺癌治療効果が有望</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109757&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109757&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 14:10:29 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109757&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AmgenがChemoCentryx社買収で手に入れた血管炎薬Tavneos販売中止をFDA提案</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109756&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109756&amp;ref=rss</guid>
		<category>ビジネス / トラブル / 安全性</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 12:31:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109756&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Transcend社もサイケデリック薬の米国超速審査の権利を手にした</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109755&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109755&amp;ref=rss</guid>
		<category>ビジネス / 世界の動き / アメリカ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 09:57:30 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109755&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 蕁麻疹を治療するNovartisの経口BTK阻害薬Rhapsidoを欧州も承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109754&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109754&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 09:41:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109754&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Compass社のDLL4xVEGF-A二重特異性抗体が胆道癌Ph2/3試験で生存改善示せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109753&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109753&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 29 Apr 2026 08:53:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109753&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Oruka社の年1回投与で事足りうる抗IL-23薬で乾癬患者の6割強の皮膚病変解消</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109752&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109752&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 28 Apr 2026 15:18:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109752&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Veradermics社の経口minoxidilがPh2/3試験で男性の髪の毛を増やした</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109751&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109751&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 28 Apr 2026 12:17:29 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109751&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] インドのSun Pharmaceutical社がOrganonを120億ドル弱で買う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109750&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109750&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 28 Apr 2026 11:25:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109750&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがAjax社を買ってPh1試験段階の2型JAK2阻害薬AJ1-11095を手に入れる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109749&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109749&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 28 Apr 2026 10:20:42 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109749&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Intellia社の体内仕立ての遺伝性血管浮腫（HAE）遺伝子編集治療のPh3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109748&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109748&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 28 Apr 2026 09:47:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109748&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 慢性腎疾患患者の収縮期血圧5 mmHg低下毎に心血管一大事発生率9-10%低下</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109747&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109747&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 28 Apr 2026 08:51:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109747&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] マラリアがのべつまくなし流行る地域の小児に長く効く抗体L9LSが予防効果あり</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109746&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109746&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / Lancet</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 27 Apr 2026 15:30:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109746&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 米国でサイケデリック薬が覚醒</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109745&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109745&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 27 Apr 2026 14:47:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109745&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Novo社の経口Wegovyが2型糖尿病小児の血糖値を有意に低下〜今年後半承認申請</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109736&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109736&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 27 Apr 2026 06:35:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109736&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ウイルス感染が癌の肺転移を防ぐ仕組みを発見</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109744&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109744&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 26 Apr 2026 16:15:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109744&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 心臓の拍動が心臓での癌細胞の増殖を防ぐ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109743&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109743&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 26 Apr 2026 15:16:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109743&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 欧州でのより初期段階の前立腺癌へのPluvicto使用承認申請をNovartisが取り下げ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109742&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109742&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 26 Apr 2026 10:03:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109742&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 意識変容薬（サイケデリック薬）を開発する3社に米国FDAが優先審査権利付与</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109741&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109741&amp;ref=rss</guid>
		<category>ビジネス / 世界の動き / アメリカ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 25 Apr 2026 17:05:07 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109741&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph2試験成績いまいちのMASH薬pemvidutideのPh3試験資金をAltimmune社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109740&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109740&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 25 Apr 2026 16:03:54 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109740&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 1歳未満〜32歳のDFNB9患者の10人に9人の聴力が遺伝子治療で改善</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109739&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109739&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sat, 25 Apr 2026 10:28:52 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109739&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] TLR7活性化薬付き抗PD-L1抗体PF08046037をPfizerがPh1試験もろとも打ち切り</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109738&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109738&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験 || 開発 / 臨床試験 / 中止</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 16:55:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109738&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AbbVieのしわ取り薬trenibotulinumtoxinE (TrenibotE) を米国が承認せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109737&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109737&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 16:43:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109737&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Grace社のくも膜下出血薬GTx-104（nimodipine）を米国承認せず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109735&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109735&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 完全回答（Complete Response Letter）</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 14:50:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109735&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Regeneron社の難聴遺伝子治療Otarmeniを米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109734&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109734&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 12:37:13 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109734&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 治療を止めた後のHIV封じにHIV専門CD8+ T細胞がだいぶ貢献しているらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109733&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109733&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 10:36:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109733&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] KeytrudaKeytrudaの乳癌治療効果を予測する末梢血の免疫指標を開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109732&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109732&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 10:18:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109732&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 異常HNRNPH2の生成を阻止するアンチセンスオリゴヌクレオチドがマウスで有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109731&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109731&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 09:40:33 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109731&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 嚢胞性線維症（CF）変異1717-1G&gt;Aを正す塩基編集手段開発</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109730&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109730&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 08:48:28 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109730&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 抗TREM2抗体が糖尿病マウスの虚血肢の治癒を助ける</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109729&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109729&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 24 Apr 2026 07:51:56 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109729&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] MEK阻害薬cobimetinibが癌増殖を促すYAP-TEAD複合体の阻害作用も担うと判明</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109728&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109728&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 16:43:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109728&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Sanofiの抗CD38抗体Sarclisa皮下注射の米国承認審査期間3か月延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109727&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109727&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認申請</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 16:23:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109727&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyがRigel社とのRIPK1阻害薬提携をすっかり打ち切る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109726&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109726&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 16:11:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109726&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Googleと組んでMerck &amp; Coが勝手に働く人AIを標準装備する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=109725&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=109725&amp;ref=rss</guid>
		<category>技術 / 情報技術（IT） / 全般</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 23 Apr 2026 14:53:50 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A109725&amp;ref=rss</comments>
	</item>
</channel>
</rss>
